Please note that nearly all the images below are hyperlinked to full articles and citations. Enjoy 😀
|
|
More Recent Posts
Older Posts
|
Links to:
Questions for Top Longs & DD Keepers:
@WaynD01 @doctor01 @Kingcole06 The Journalist: @agamemnus Former Executive in Pharma: @LeftyT Sharp DD Seeker and Provider: @Bobby720 Financials & Share Structure: @mailman1961 Also:
Special Thanks to:
Additional DD provider:
@X2020 |
Mitton believes that KemPharm has positioned itself to be “a prime buyout candidate or a strong successful go-it-alone entity.
The choice is now entirely in KemPharm's hands.”
Mitton added that “KemPharm’s pride and joy is its ability to develop new drugs on the back of others’ work and money.”
The company does this by utilizing the 505(b)(2) pathway.
It takes existing drugs already on the market and investigates how to make significant improvements.
Those improvements could range from onset or duration, ability to be abused or a whole host of other parameters.
This technique of improving can be used across the entire spectrum of therapeutics, so the possibilities are endless.
It actually has been called a “license to steal” by some.
The company can piggy-back on the data and dollars that have been invested by others, to develop a brand new molecule that will get full patent protection.
Mitton concluded, “It is akin to the Golden Goose that will just keep laying golden egg after golden egg.
Dr. Mickle has stated that ‘given sufficient funds, he doesn’t have enough life left, to develop all of the possibilities.
"This is perhaps the most valuable asset that KemPharm possesses."
The choice is now entirely in KemPharm's hands.”
Mitton added that “KemPharm’s pride and joy is its ability to develop new drugs on the back of others’ work and money.”
The company does this by utilizing the 505(b)(2) pathway.
It takes existing drugs already on the market and investigates how to make significant improvements.
Those improvements could range from onset or duration, ability to be abused or a whole host of other parameters.
This technique of improving can be used across the entire spectrum of therapeutics, so the possibilities are endless.
It actually has been called a “license to steal” by some.
The company can piggy-back on the data and dollars that have been invested by others, to develop a brand new molecule that will get full patent protection.
Mitton concluded, “It is akin to the Golden Goose that will just keep laying golden egg after golden egg.
Dr. Mickle has stated that ‘given sufficient funds, he doesn’t have enough life left, to develop all of the possibilities.
"This is perhaps the most valuable asset that KemPharm possesses."
The data for KP415 support the claim of a 30-minute onset of action, a smooth plasma profile and up to 13-hour duration. Anyone living in a household with a member or members afflicted with ADHD, knows how much of vast improvement a 30-minute onset would be when compared to up to 90 minutes. That means the medication would be working by the time children are getting dressed and ready to go, instead of kicking in when they are dropped off at school. In addition, the 13-hour duration would be a lifesaver. It would allow the child to finish dinner and homework, without the need to having a booster medication later in the day.
If you like this transcript format on transcriptshare, contact any other companies you like and ask them to use our service. [email protected]. Stocktwits: @agamemnus https://seekingalpha.com/author/agamemnus/articles#regular_articles Follow me for instant emails on new articles. Twitter: @agamemnus_dev
|